A presumed case of Darbepoetin‐induced myocardial infarction in the patient with MDS‐RARS

Abstract Our case is only the 2nd such reported case of atherothrombosis from ESAs and highlights the increased risk of cardiovascular events in patients receiving erythropoietin‐stimulating agents specially patients with underlying MDS where targeting a lower hemoglobin goal and optimizing other ca...

Full description

Bibliographic Details
Main Authors: Aneeqa Ahsan Zafar, Peter Kouides
Format: Article
Language:English
Published: Wiley 2020-04-01
Series:Clinical Case Reports
Subjects:
Online Access:https://doi.org/10.1002/ccr3.2728
_version_ 1818388925826203648
author Aneeqa Ahsan Zafar
Peter Kouides
author_facet Aneeqa Ahsan Zafar
Peter Kouides
author_sort Aneeqa Ahsan Zafar
collection DOAJ
description Abstract Our case is only the 2nd such reported case of atherothrombosis from ESAs and highlights the increased risk of cardiovascular events in patients receiving erythropoietin‐stimulating agents specially patients with underlying MDS where targeting a lower hemoglobin goal and optimizing other cardiovascular risk factors might be beneficial in preventing future cardiovascular mortality.
first_indexed 2024-12-14T04:33:35Z
format Article
id doaj.art-7a286fcbb1394920b40a4b1d84c9eda3
institution Directory Open Access Journal
issn 2050-0904
language English
last_indexed 2024-12-14T04:33:35Z
publishDate 2020-04-01
publisher Wiley
record_format Article
series Clinical Case Reports
spelling doaj.art-7a286fcbb1394920b40a4b1d84c9eda32022-12-21T23:17:02ZengWileyClinical Case Reports2050-09042020-04-018465866010.1002/ccr3.2728A presumed case of Darbepoetin‐induced myocardial infarction in the patient with MDS‐RARSAneeqa Ahsan Zafar0Peter Kouides1Internal Medicine Rochester General Hospital Rochester NY USALipson Cancer Center Mary M Gooley Hemophilia Center Rochester General Hospital Rochester NY USAAbstract Our case is only the 2nd such reported case of atherothrombosis from ESAs and highlights the increased risk of cardiovascular events in patients receiving erythropoietin‐stimulating agents specially patients with underlying MDS where targeting a lower hemoglobin goal and optimizing other cardiovascular risk factors might be beneficial in preventing future cardiovascular mortality.https://doi.org/10.1002/ccr3.2728acute coronary syndromeanemia with ringed sideroblastsclonal hematopoiesis of indeterminate potentialerythropoietin‐stimulating agentsmyelodysplastic syndromes
spellingShingle Aneeqa Ahsan Zafar
Peter Kouides
A presumed case of Darbepoetin‐induced myocardial infarction in the patient with MDS‐RARS
Clinical Case Reports
acute coronary syndrome
anemia with ringed sideroblasts
clonal hematopoiesis of indeterminate potential
erythropoietin‐stimulating agents
myelodysplastic syndromes
title A presumed case of Darbepoetin‐induced myocardial infarction in the patient with MDS‐RARS
title_full A presumed case of Darbepoetin‐induced myocardial infarction in the patient with MDS‐RARS
title_fullStr A presumed case of Darbepoetin‐induced myocardial infarction in the patient with MDS‐RARS
title_full_unstemmed A presumed case of Darbepoetin‐induced myocardial infarction in the patient with MDS‐RARS
title_short A presumed case of Darbepoetin‐induced myocardial infarction in the patient with MDS‐RARS
title_sort presumed case of darbepoetin induced myocardial infarction in the patient with mds rars
topic acute coronary syndrome
anemia with ringed sideroblasts
clonal hematopoiesis of indeterminate potential
erythropoietin‐stimulating agents
myelodysplastic syndromes
url https://doi.org/10.1002/ccr3.2728
work_keys_str_mv AT aneeqaahsanzafar apresumedcaseofdarbepoetininducedmyocardialinfarctioninthepatientwithmdsrars
AT peterkouides apresumedcaseofdarbepoetininducedmyocardialinfarctioninthepatientwithmdsrars
AT aneeqaahsanzafar presumedcaseofdarbepoetininducedmyocardialinfarctioninthepatientwithmdsrars
AT peterkouides presumedcaseofdarbepoetininducedmyocardialinfarctioninthepatientwithmdsrars